Gene: LPCAT1

79888
AGPAT10|AGPAT9|AYTL2|LPCAT-1|PFAAP3|lpcat|lysoPAFAT
lysophosphatidylcholine acyltransferase 1
protein-coding
5p15.33
Ensembl:ENSG00000153395 MIM:610472 Vega:OTTHUMG00000131017 UniprotKB:Q8NF37
NG_051622.1
SNP Mapped
2   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.765e-2 (AD)  9.121e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs4608970chr5:1519082 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs2963282chr5:1512093 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg07902156chr5:1495284LPCAT13.340e-8Maternal smoking in pregnancy27040690
cg22894329chr5:1495356LPCAT16.550e-9Maternal smoking in pregnancy27040690
cg05661533chr5:1495043LPCAT12.900e-8Smoking27651444
cg07902156chr5:1495284LPCAT15.300e-8Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RIC8A0.908
DLST0.905
CTSA0.902
RNF400.902
PMPCA0.901
CSNK1D0.901
TMEM2480.901
TMUB20.899
KDM1A0.898
SEC24C0.898

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.701
OR4F29-0.635
CTNNA3-0.371
TRPV5-0.327
C5orf64-0.326
KLRB1-0.319
OR6C74-0.313
C9orf153-0.302
IFNG-0.289
TNFRSF13B-0.286

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5321622-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine"[PIK3CA gene mutant form results in increased susceptibility to 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine] which results in decreased expression of LPCAT1 mRNA"20453058
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPCAT1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPCAT1 mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 affects the expression of LPCAT1 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of LPCAT1 mRNA27153756
D018501Antirheumatic AgentsAntirheumatic Agents results in decreased expression of LPCAT1 mRNA24449571
D001151ArsenicArsenic affects the methylation of LPCAT1 gene25304211
C006632arsenic trioxide[Tretinoin co-treated with arsenic trioxide] results in increased expression of LPCAT1 mRNA15894607
D017638Asbestos, Crocidolite"Asbestos, Crocidolite results in increased expression of LPCAT1 mRNA"25351596
D001280AtrazineAtrazine affects the expression of LPCAT1 mRNA25929836
D001280AtrazineAtrazine results in decreased expression of LPCAT1 mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of LPCAT1 mRNA20064835
D001564Benzo(a)pyreneBenzo(a)pyrene promotes the reaction [AHR protein binds to LPCAT1 promoter]19654925
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of LPCAT1 mRNA19770486|2156981
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of LPCAT1 mRNA"19150397|2038263
C006780bisphenol Abisphenol A results in increased expression of LPCAT1 mRNA29275510
C006780bisphenol Abisphenol A affects the expression of LPCAT1 mRNA21786754
C006780bisphenol Abisphenol A affects the expression of LPCAT1 mRNA25181051
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LPCAT1 mRNA28628672
D0151248-Bromo Cyclic Adenosine Monophosphate[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPCAT1 mRNA16997883
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of LPCAT1 mRNA15336504
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of LPCAT1 protein24527689
D002220CarbamazepineCarbamazepine affects the expression of LPCAT1 mRNA25979313
D002737ChloropreneChloroprene results in decreased expression of LPCAT1 mRNA23125180
D004390Chlorpyrifos[Copper co-treated with Chlorpyrifos] results in decreased expression of LPCAT1 mRNA21356183
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LPCAT1 mRNA20938992
C039671ciglitazone[ciglitazone binds to PPARG protein alternative form] which results in increased expression of LPCAT1 mRNA16197558
C018021cobaltous chloridecobaltous chloride results in increased expression of LPCAT1 mRNA19376846
C018021cobaltous chloridecobaltous chloride results in decreased expression of LPCAT1 mRNA24386269
D003300Copper[Copper co-treated with Chlorpyrifos] results in decreased expression of LPCAT1 mRNA21356183
D003300CopperCopper results in decreased expression of LPCAT1 mRNA21356183
D016572CyclosporineCyclosporine results in decreased expression of LPCAT1 mRNA25562108|2798913
D003907Dexamethasone[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPCAT1 mRNA16997883
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LPCAT1 mRNA28628672
D004147DioxinsDioxins affects the expression of LPCAT1 mRNA20463971
D004317DoxorubicinLPCAT1 protein affects the susceptibility to Doxorubicin16217747
D004791Enzyme Inhibitors[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of LPCAT1 protein23301498
D005020Ethyl MethanesulfonateEthyl Methanesulfonate results in decreased expression of LPCAT1 mRNA23649840
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LPCAT1 mRNA20938992
D005947Glucose[INS protein co-treated with Glucose] results in increased expression of LPCAT1 mRNA22634610
D017313FenretinideFenretinide results in increased expression of LPCAT1 mRNA28973697
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LPCAT1 mRNA28628672
C051890irinotecanirinotecan analog results in decreased expression of LPCAT1 mRNA18927307
D0150561-Methyl-3-isobutylxanthine[Dexamethasone co-treated with 8-Bromo Cyclic Adenosine Monophosphate co-treated with 1-Methyl-3-isobutylxanthine] results in increased expression of LPCAT1 mRNA16997883
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of LPCAT1 mRNA28628672
C410337K 7174K 7174 results in increased expression of LPCAT1 mRNA24086573
D008095Lithocholic AcidLithocholic Acid results in increased expression of LPCAT1 mRNA21480330|2303421
D008095Lithocholic AcidNR1H4 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT1 mRNA]21480330
D008095Lithocholic AcidSMAD3 protein promotes the reaction [Lithocholic Acid results in increased expression of LPCAT1 mRNA]23034213
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of LPCAT1 mRNA20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of LPCAT1 mRNA23103053
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of LPCAT1 mRNA23649840
C583365N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide"N-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide results in decreased expression of LPCAT1 mRNA"29244179
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of LPCAT1 mRNA"25554681
C028007nickel monoxidenickel monoxide results in increased expression of LPCAT1 mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of LPCAT1 mRNA22714537
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of LPCAT1 mRNA25729387
D010416PentachlorophenolPentachlorophenol results in increased expression of LPCAT1 mRNA24642059
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of LPCAT1 mRNA19710929
D011441PropylthiouracilPropylthiouracil results in increased expression of LPCAT1 mRNA24780913
C017947sodium arsenitesodium arsenite results in decreased stability of LPCAT1 mRNA25493608
C017947sodium arsenitesodium arsenite results in increased expression of LPCAT1 mRNA22714537|2859598
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of LPCAT1 mRNA24680724
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin promotes the reaction [AHR protein binds to LPCAT1 promoter]19654925
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of LPCAT1 mRNA22298810
D013849ThimerosalThimerosal results in increased expression of LPCAT1 mRNA24675092
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of LPCAT1 mRNA25729387
D014212Tretinoin[Tretinoin co-treated with arsenic trioxide] results in increased expression of LPCAT1 mRNA15894607
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LPCAT1 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of LPCAT1 mRNA24935251|2627250
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of LPCAT1 mRNA"26179874
C013320tris(2-butoxyethyl) phosphatetris(2-butoxyethyl) phosphate affects the expression of LPCAT1 mRNA29024780
D014415TunicamycinTunicamycin results in decreased expression of LPCAT1 mRNA22378314
D014635Valproic AcidValproic Acid affects the expression of LPCAT1 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of LPCAT1 mRNA29154799
D014638VanadatesVanadates results in decreased expression of LPCAT1 mRNA22714537
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of LPCAT1 gene25560391
C025643vinclozolinvinclozolin affects the expression of LPCAT1 mRNA19015723
C025643vinclozolinvinclozolin results in increased expression of LPCAT1 mRNA23869203

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:00038411-acylglycerol-3-phosphate O-acyltransferase activity-TAS-  
GO:0005509calcium ion binding-IEA-  
GO:00471442-acylglycerol-3-phosphate O-acyltransferase activity-TAS-  
GO:00471591-alkenylglycerophosphocholine O-acyltransferase activity-IEA-  
GO:00471841-acylglycerophosphocholine O-acyltransferase activity-IDA21498505  
GO:00471841-acylglycerophosphocholine O-acyltransferase activity-ISS-  
GO:00471911-alkylglycerophosphocholine O-acyltransferase activity-IEA-  
GO:00471921-alkylglycerophosphocholine O-acetyltransferase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0006654phosphatidic acid biosynthetic process-TAS-  
GO:0006656phosphatidylcholine biosynthetic process-TAS-  
GO:0008654phospholipid biosynthetic process-ISS-  
GO:0036148phosphatidylglycerol acyl-chain remodeling-TAS-  
GO:0036151phosphatidylcholine acyl-chain remodeling-IDA21498505  
GO:0036151phosphatidylcholine acyl-chain remodeling-TAS-  
GO:0043129surfactant homeostasis-IEA-  
GO:0043312neutrophil degranulation-TAS-  
GO:0045732positive regulation of protein catabolic process-IEA-  
GO:0060041retina development in camera-type eye-IEA-  
GO:2001246negative regulation of phosphatidylcholine biosynthetic process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0005783endoplasmic reticulum-IDA21498505  
GO:0005783endoplasmic reticulum-ISS-  
GO:0005789endoplasmic reticulum membrane-TAS-  
GO:0005794Golgi apparatus-ISS-  
GO:0005811lipid droplet-IDA21498505  
GO:0005886plasma membrane-TAS-  
GO:0016020membrane-HDA19946888  
GO:0016021integral component of membrane-IEA-  
GO:0035577azurophil granule membrane-TAS-  
KEGG ID KEGG Term
hsa00564Glycerophospholipid metabolism
hsa00565Ether lipid metabolism
hsa01100Metabolic pathways
Reactome ID Reactome Term Evidence
R-HSA-1430728MetabolismTAS
R-HSA-1482788Acyl chain remodelling of PCTAS
R-HSA-1482925Acyl chain remodelling of PGTAS
R-HSA-1483166Synthesis of PATAS
R-HSA-1483191Synthesis of PCTAS
R-HSA-1483206Glycerophospholipid biosynthesisTAS
R-HSA-1483257Phospholipid metabolismTAS
R-HSA-168249Innate Immune SystemTAS
R-HSA-168256Immune SystemTAS
R-HSA-556833Metabolism of lipidsTAS
R-HSA-6798695Neutrophil degranulationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal